All NGS genomic profile results are reviewed and interpreted by our OncoHelix pathology team of bioinformaticians, molecular pathologists and anatomical pathologists before sending the final results to the ordering physician.
OncoHelix NGS Report
The report will identify 3 classifications of relevance:
A Genomic tumour mutations of strong clinical significance
This means there has been a mutation detected that has a matched targeted therapy available or a novel drug currently being investigated in clinical trials.
B Genomic tumour mutations of potential clinical significance
This means there has been a tumour mutation detected however there may not be a known or approved drug therapy available or the sample provided may not have had enough tissue to provide a conclusive result.
C Genomic tumour mutations of uncertain clinical significance
This means there may be mutations detected however a matched treatment may not be available at the time of the report.